medigraphic.com
ISSN 1561-3046 (Electronic)

2021, Number 2

<< Back Next >>

Rev Cub Med Mil 2021; 50 (2)

Transient acute renal failure after coronary thrombolysis with streptokinase

Vega CR, Vega JJ

Language: Spanish
References: 13
Page:
PDF size: 261.73 Kb.


ABSTRACT

Introduction: There are currently more than 150 medications related to the appearance of rhabdomyolysis and transient acute renal failure. Streptokinase can be one of them.
Objective: Presenting a case the administration of streptokinase as a possible cause of acute, transient renal failure.
Case report: A 38-year-old patient with a previous health history and 81 mg creatinine per liter days before admission, suffers acute myocardial infarction and after streptokinase thrombolysis he suffers severe muscle pain, nausea, vomiting, severe low back pain, creatinine ascends progressively and progressive oligoanuria that evolves until two weeks when it begins to return. At 21 days with 116 mg creatinine per liter, coronary angiography was performed with normal coronaries.
Comments: The causes of transient acute renal failure may be rhabdomyolysis associated with abnormalities of the metabolism of ATP and immune disorders, caused by the administration of streptokinase. His coronary angiography was completely normal.


REFERENCES

  1. Summachiwakij S, Sachmechi I. Rhabdomyolysis induced by nonstrenuous exercise in a patient with graves' disease. Case Rep. Endocrinol. 2014 [acceso: 04/04/2019];2014:286450. Disponible en: Disponible en: https://www.hindawi.com/journals/crie/2014/286450/

  2. Lee BJ, Zand L, Manek NJ, Hsiao LL, Babovic-Vuksanovic D, Wylam ME, et al. Physical therapy-induced rhabdomyolysis and acute kidney injury associated with reduced activity of muscle lactate dehydrogenase A. Arthritis Care Res (Hoboken). 2011 Dic. [acceso: 05/04/2019];63(12):1782-6. Disponible en: Disponible en: https://onlinelibrary.wiley. com/doi/full/10.1002/acr.20584

  3. 3 . Luzardo L, Silvariño R, Boggia J, Noboa O, Gadola L. Rabdomiólisis por hipopotasemia severa. Rev Med Chile. 2014 May [acceso: 08/04/2019];142(5):651-5. Disponible en: Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000500015

  4. Oh RC, Arter JL, Tiglao SM, Larson SL. Exertional rhabdomyolysis: a case series of 30 hospitalized patients. Mil Med. Feb 2015 [acceso: 10/04/2019];180(2):201-7. Disponible en: Disponible en: https://academic.oup.com/milmed/article/180/2/201/4159997

  5. Cigales Reyes MJ. Dolor lumbar por estreptoquinasa recombinante. Presentación de un caso. Rev Cubana Farm. 2009 Mayo-Ago [acceso: 24/04/2019];43(2):1961. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S00347515 2009 000200013

  6. Fears R, Ferres H, Glasgow E, Standring R, Hogg K, Gemmill JD, et al. Monitoring of Streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase Ig G. Br Heart J. 1992 [acceso: 06/05/2019];68(2):167-70. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025006/pdf/brheartj00032-0007.pdf

  7. Jalihal S, Morris GK. Antistreptokinase titres after intravenous streptokinase. Lancet 1990 [acceso; 10/05/2019];8683(335):184-5. Disponible in: Disponible in: https://www.sciencedirect. com/science/article/pii/014067369090276B

  8. Garg S, Chandrashekhar YS, Nanda Kumar DM. Antistreptokinase Antibodies Before and After Streptokinase Therapy in Patients with Acute Myocardial Infarction from Areas Endemic for Streptococcal Infection and Influence on Reperfusion Rates. Am J Cardiol 1994 [acceso: 13/05/2019]; 74(2):187-9. Disponible en: Disponible en: https://www.ncbi. nlm.nih.gov/pmc/articles/PMC1025006/pdf/brheartj00032-0007.pdf

  9. Limón-Jiménez E, Pineda Flores SA, Rodríguez-Wong U. Aspectos farmacodinámicos y farmacocinéticos de la estreptoquinasa. Rev Hosp Jua Méx. 2014 [acceso: 15/05/2019];81(3):188-92. Disponible en: Disponible en: https://www.medigraphic. com/pdfs/juarez/ju-2014/ju143i.pdf

  10. Blas Betancourt Y, Marrero Miragaya M, Jiménez López G, Valenzuela Silva C, García Iglesias E, Hernández Bernal F, et al. Programa farmacovigilancia para controlar las reacciones adversas de la estreptoquinasa recombinante en el infarto agudo de Miocardio. BMC Clinical Pharmacology, 2005 [acceso: 31/05/2019];5:5-5. Disponible en: Disponible en: https://viaclinica.com/article.php?pmc_id=1291362

  11. León Jiménez J, Camacho Freire S, Gutiérrez Barrio A, Gamaza Chulián S, Sánchez MA, Agarrado Luna A, et al. Infarto agudo de miocardio sin lesiones angiográficas: lo que la coronariografía no revela. Archivos de Cardiología de México. 2015 [acceso: 01/06/2019];85(2):93-170. Disponible en: Disponible en: https://www.elsevier.es/es-revista-archivos-cardiologia-mexico-293-pdf-S1405994014001335

  12. Berry C. El enigma de la angina sin obstrucciones coronarias. Síndromes coronarios estables: ¿Qué son INOCA y MINOCA? Stable Coronary Syndromes: The Case for Consolidating the Nomenclature of Stable Ischemic Heart Disease. Circulation. 2017[Acceso: 01/06/2019];136:437-39. Disponible en: Disponible en: https://www.intramed.net/ contenidover.asp?contenidoid=92899

  13. Zuluaga Quintero C, Cano Granda C. Infarto agudo de miocardio sin enfermedad coronaria ateroesclerótica obstructiva. Iatreia. 2018 Oct-Dic [acceso: 05/04/2019];31(4):371-9. Disponible en: Disponible en: http://www.scielo.org.co/pdf/iat/v31n4/0121-0793-iat-31-04-00371.pdf




2020     |     www.medigraphic.com